Amgen Stock News

The global Cell And Gene Therapy market is expected to reach US$ 14.6 Billion by 2027, with a CAGR of 13.8% from 2021 to 2027. The high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments

DUBLIN--(BUSINESS WIRE)--The "Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global breast cancer monoclonal antibodies market is expected to grow from $12.67 billion in 2020 to $13.76 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The market is expected to reach $18.61 billion in 2025 at a CAGR of 8%. Major players in the breast cancer monoclonal antibodies (mAb

Amgen Inc. is a biotech company specializing in therapeutics for inflammation, oncology, hematology, bone health, cardiovascular disease, and neuroscience areas. Amgen has 34 pipeline programs in phas

Glioblastoma is a tumor that can develop in the brain or spinal cord and is very aggressive. Glioblastoma develops in astrocytes, the cells that support nerve cells. Glioblastoma can affect anyone at any age, but it occurs more often in

2 Great Blue Chips To Buy In December

Shares of Amgen Inc. (NASDAQ:AMGN) have received an average recommendation of Hold from the eighteen research firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating on the company. The average 12 []

A technician holds a laboratory mouse at the Jackson Laboratory in Bar Harbor, Maine, which ships more than two million mice a year to researchers. Eight years ago, a team of researchers launched a project to carefully repeat influential lab experiments in cancer research. They recreated 50 experiments the type of work with mice and test tubes that sets the stage for new cancer drugs. In newly reported results, they say about half of the scientific claims didnt hold up. | Robert F. Bukaty / AP Eight years ago, researchers launched a project to carefully repeat influential lab experiments in cancer research. It turns out that about half of the scientific claims didnt hold up. Eight years ago, a team of researchers launched a project to carefully repeat early but influential lab experiments in cancer research. They recreated 50 experiments the type of preliminary research with mice and test tubes that sets the stage for new cancer drugs. Now, in newly reported results, they say that about half of the scientific claims didnt hold up. The truth is we fool ourselves, said Dr.

DUBLIN--(BUSINESS WIRE)--The "Global Bleeding Disorder Treatment Market (2021-2026) by Type, Drug Class, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Bleeding Disorder Treatment Market is estimated to be USD 13.5 Bn in 2021 and is expected to reach USD 18.6 Bn by 2026, growing at a CAGR of 10%. The factors driving the growth of the bleeding disorder treatment market a

Townsend Asset Management Corp NC ADV cut its position in Amgen Inc. (NASDAQ:AMGN) by 5.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,301 shares of the medical research companys stock after selling 72 shares during the quarter. Townsend Asset Management Corp NC []

DUBLIN--(BUSINESS WIRE)--The "Psoriatic Arthritis Treatment Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global psoriatic arthritis treatment market is expected to grow from $7.26 billion in 2020 to $7.89 billion in 2021 at a compound annual growth rate (CAGR) of 8.7%. The market is expected to reach $11.34 billion in 2025 at a CAGR of 9%. Major players in the psoriatic arthritis treatment market are AbbVie, Amgen

Sarasin & Partners LLP grew its stake in Amgen Inc. (NASDAQ:AMGN) by 3.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,203,799 shares of the medical research companys stock after purchasing an additional 40,507 shares during the quarter. Amgen comprises approximately []

Palouse Capital Management Inc. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 16,179 shares of the medical research companys stock after selling 463 shares during the quarter. Amgen makes up 1.5% of Palouse Capital Management Inc.s portfolio, making the stock its 22nd []